| pubmed-article:11401916 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11401916 | lifeskim:mentions | umls-concept:C2349001 | lld:lifeskim |
| pubmed-article:11401916 | lifeskim:mentions | umls-concept:C0681850 | lld:lifeskim |
| pubmed-article:11401916 | lifeskim:mentions | umls-concept:C1706203 | lld:lifeskim |
| pubmed-article:11401916 | lifeskim:mentions | umls-concept:C2697811 | lld:lifeskim |
| pubmed-article:11401916 | lifeskim:mentions | umls-concept:C0524930 | lld:lifeskim |
| pubmed-article:11401916 | lifeskim:mentions | umls-concept:C0282515 | lld:lifeskim |
| pubmed-article:11401916 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:11401916 | lifeskim:mentions | umls-concept:C1550501 | lld:lifeskim |
| pubmed-article:11401916 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:11401916 | lifeskim:mentions | umls-concept:C0086156 | lld:lifeskim |
| pubmed-article:11401916 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:11401916 | pubmed:dateCreated | 2001-6-12 | lld:pubmed |
| pubmed-article:11401916 | pubmed:abstractText | Individuals who receive life-saving organ transplants and the required immunosuppression often develop secondary cancers. One of the most common secondary cancers is nonmelanoma skin cancer in sun-exposed areas. Attempts to prevent these cancers have not been successful. Difluoromethylornithine (DFMO), a suicide inhibitor of ornithine decarboxylase (ODC), is a known experimental cancer prevention agent that is being evaluated in a number of human cancer prevention trials. This report describes a Phase I trial in 18 organ transplant recipients, randomized to 1.0 and 0.5 g of DFMO or a placebo, designed to look at short-term toxicities over 28 days as well as the impact of DFMO on two biological parameters, skin polyamines and 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ODC activity. Blood levels of DFMO were also measured. The results indicate that DFMO was well tolerated over the 28-day period. The TPA-induced ODC activity in 3-mm skin biopsies was significantly lowered by 80 and 67% at the two dose levels. Polyamine levels were not affected significantly except for putrescine at the 0.5-g level. Blood levels of DFMO were about two times higher than expected, based on our prior pharmacokinetic studies. Our studies indicate that DFMO is a reasonable agent that should be tested further in larger Phase 2b trials in this population as a chemopreventive agent. TPA-induced ODC activity appears to be a relevant intermediate biological assay. | lld:pubmed |
| pubmed-article:11401916 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11401916 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11401916 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11401916 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11401916 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11401916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11401916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11401916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11401916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11401916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11401916 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11401916 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:11401916 | pubmed:issn | 1055-9965 | lld:pubmed |
| pubmed-article:11401916 | pubmed:author | pubmed-author:CarboneP PPP | lld:pubmed |
| pubmed-article:11401916 | pubmed:author | pubmed-author:ThomasJ PJP | lld:pubmed |
| pubmed-article:11401916 | pubmed:author | pubmed-author:VermaA KAK | lld:pubmed |
| pubmed-article:11401916 | pubmed:author | pubmed-author:PaulKK | lld:pubmed |
| pubmed-article:11401916 | pubmed:author | pubmed-author:DouglasJ AJA | lld:pubmed |
| pubmed-article:11401916 | pubmed:author | pubmed-author:PirschJ DJD | lld:pubmed |
| pubmed-article:11401916 | pubmed:author | pubmed-author:SnowSS | lld:pubmed |
| pubmed-article:11401916 | pubmed:author | pubmed-author:LarsonP OPO | lld:pubmed |
| pubmed-article:11401916 | pubmed:author | pubmed-author:TutschK DKD | lld:pubmed |
| pubmed-article:11401916 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11401916 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:11401916 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11401916 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11401916 | pubmed:pagination | 657-61 | lld:pubmed |
| pubmed-article:11401916 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:meshHeading | pubmed-meshheading:11401916... | lld:pubmed |
| pubmed-article:11401916 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11401916 | pubmed:articleTitle | Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. | lld:pubmed |
| pubmed-article:11401916 | pubmed:affiliation | University of Wisconsin Comprehensive Cancer Center, Department of Medicine, University of Wisconsin Medical School, Madison, Wisconsin 53792, USA. | lld:pubmed |
| pubmed-article:11401916 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11401916 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11401916 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11401916 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11401916 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:11401916 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11401916 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11401916 | lld:pubmed |
